Genmab News

Genmab News

Date Title View
Nov 12, 2019
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
20191112_CA55_Man Empl Transaction
Nov 12, 2019
Capital Increase in Genmab as a Result of Employee Warrant Exercise
20191112_CA54_Warrant Exercise
Nov 06, 2019
Genmab Announces Financial Results for the First Nine Months of 2019
191106_Q3 2019 Interim Report
Nov 06, 2019
Genmab Announces Data to be Presented at 2019 ASH Annual Meeting
191106_MR13_ASH Abstracts
Oct 30, 2019
David Eatwell to Retire as Chief Financial Officer of Genmab
191030_CA52_DAE
Oct 30, 2019
Genmab’s Financial Calendar for 2020
191030_CA51_Financial Calendar 2020
Oct 22, 2019
Genmab A/S has published its Articles of Association
Articles of Association - October 11 2019 (UK)
Oct 18, 2019
CHMP Issues Positive Opinion Recommending DARZALEX® (Daratumumab) in Combination with Lenalidomide and Dexamethasone in Frontline Multiple Myeloma
191018_CA50_MAIA CHMP Opinion
Oct 15, 2019
Genmab Announces Net Sales of DARZALEX® (daratumumab) for Third Quarter of 2019
191015_CA49_Dara Q3 Sales
Oct 11, 2019
Grant of Restricted Stock Units and Warrants to Employees in Genmab
20191011_CA48_warrant grant
Oct 02, 2019
Genmab A/S has published its Articles of Association
Articles of Association - October 1, 2019 (UK)
Oct 01, 2019
Capital Increase in Genmab as a Result of Employee Warrant Exercise
191001_CA47_Warrant Exercise
Sep 26, 2019
Genmab Announces U.S. FDA Approval of DARZALEX® (daratumumab) in Combination with Bortezomib, Thalidomide and Dexamethasone for Frontline Multiple Myeloma
190926_CA46_CASSIOPEIA US Approval
Sep 13, 2019
Genmab Announces Positive Topline Results in Phase III Study of Daratumumab in Combination with Carfilzomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma
190913_CA45_CANDOR
Sep 13, 2019
Detailed Results from the Phase III ASCLEPIOS I & II Studies of Ofatumumab in Patients with Relapsing Multiple Sclerosis Presented at ECTRIMS
190913_CA44_Ofatumumab Data at ECTRIMS
Sep 09, 2019
Genmab and Tempus Enter into Strategic Collaboration Agreement
190909_i12_Tempus
Aug 30, 2019
Genmab’s Partner for Ofatumumab, Novartis, Reports that Ofatumumab Demonstrates Superiority Versus Teriflunomide in Two Head-to-Head Phase III Multiple Sclerosis Studies
190830_CA43_Ofatumumab RMS Data
Aug 22, 2019
Genmab Announces Approval of DARZALEX® (daratumumab) in Frontline Multiple Myeloma in Japan
190822_CA_42_ALCYONE Japan approval
Aug 21, 2019
Genmab Announces Preliminary Data to be Presented at IASLC 2019 World Conference on Lung Cancer
190821_i11_EV at WCLC
Aug 21, 2019
Genmab A/S has published its Articles of Association
Articles of Association - August 20, 2019 (UK)
Aug 20, 2019
Capital Increase in Genmab as a Result of Employee Warrant Exercise
190820_CA41_warrant exercise
Aug 19, 2019
Daratumumab Abstracts Selected for Presentation at 17th International Myeloma Workshop
190819_i10_IMW
Aug 14, 2019
Genmab Announces Financial Results for the First Half of 2019 and Updates 2019 Financial Guidance
190814_CA40_Q2 2019 Interim Report
Jul 23, 2019
Genmab A/S has published its Articles of Association
Articles of Association - July 17 2019 II (UK)
Jul 23, 2019
Genmab Announces the Closing of Over-Allotment Option in Initial Public Offering of American Depositary Shares (ADSs) in the United States and Registration of Capital Increase
190723_CA39_Overallotment Closing